07:32 AM EDT, 04/30/2025 (MT Newswires) -- Novartis AG ( NVS ) has agreed to acquire Regulus Therapeutics ( RGLS ) for an initial payment of $7.00 per share in cash at closing, or $800 million, Regulus said Wednesday.

Regulus shareholders will receive a contingent value right of $7.00 per share, contingent on the achievement of regulatory approval of Regulus' farabursen. Regulus said that the total deal consideration, including the contingent payment, would be about $1.7 billion. The deal is expected to close in H2, subject to the satisfaction of or waiver of customary closing conditions.

"With limited treatment options currently available for patients suffering from [autosomal dominant polycystic kidney disease], farabursen represents a potential first-in-class medicine with a profile that may provide enhanced efficacy, tolerability and safety versus standard of care," said Shreeram Aradhye, president, development and chief medical officer at Novartis ( NVS ).